NASDAQ:ALDX - Aldeyra Therapeutics Stock Price, Forecast & News

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) released its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.14. View Aldeyra Therapeutics' Earnings History.

Aldeyra Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Aldeyra Therapeutics.

3 brokerages have issued 1-year target prices for Aldeyra Therapeutics' stock. Their forecasts range from $20.00 to $38.00. On average, they anticipate Aldeyra Therapeutics' stock price to reach $30.33 in the next year. This suggests a possible upside of 418.5% from the stock's current price. View Analyst Price Targets for Aldeyra Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aldeyra Therapeutics.

News headlines about ALDX stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aldeyra Therapeutics earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Aldeyra Therapeutics.

Aldeyra Therapeutics saw a drop in short interest during the month of January. As of January 15th, there was short interest totalling 562,500 shares, a drop of 5.2% from the December 31st total of 593,600 shares. Based on an average daily volume of 301,800 shares, the short-interest ratio is currently 1.9 days. Currently, 2.3% of the shares of the company are sold short. View Aldeyra Therapeutics' Current Options Chain.

Some companies that are related to Aldeyra Therapeutics include DiaMedica Therapeutics (DMCAF), ImmunoGen (IMGN), Vectura Group (VEGPF), Cara Therapeutics (CARA), Urogen Pharma (URGN), AC Immune (ACIU), Kadmon (KDMN), Morphic (MORF), Crinetics Pharmaceuticals (CRNX), Magenta Therapeutics (MGTA), Kura Oncology (KURA), MacroGenics (MGNX), Milestone Pharmaceuticals (MIST), Atreca (BCEL) and Neoleukin Therapeutics (NLTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include Micron Technology (MU), Amarin (AMRN), TherapeuticsMD (TXMD), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO), Amicus Therapeutics (FOLD), AbbVie (ABBV), Aerie Pharmaceuticals (AERI), Catabasis Pharmaceuticals (CATB) and Corbus Pharmaceuticals (CRBP).

Aldeyra Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Woodstock Corp (0.48%) and Mesirow Financial Investment Management Inc. (0.24%). Company insiders that own Aldeyra Therapeutics stock include Ben Bronstein, David Mcmullin, Jesse I Treu, Joshua Reed, Richard Douglas and Todd C Brady. View Institutional Ownership Trends for Aldeyra Therapeutics.

ALDX stock was sold by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc.. View Insider Buying and Selling for Aldeyra Therapeutics.

ALDX stock was acquired by a variety of institutional investors in the last quarter, including Woodstock Corp. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Ben Bronstein, David Mcmullin, Joshua Reed, Richard Douglas and Todd C Brady. View Insider Buying and Selling for Aldeyra Therapeutics.

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALDX stock can currently be purchased for approximately $5.85.

Aldeyra Therapeutics has a market capitalization of $163.53 million. The biotechnology company earns $-38,890,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. View Additional Information About Aldeyra Therapeutics.

The official website for Aldeyra Therapeutics is http://www.ampliphibio.com/.

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]